We are live on ! Find out more

Intelligent Bio Solutions

INBS

Market cap $7.14M

2.36 USD

+0.09

3.96%

At close Updated Aug 28, 4:00 PM EDT

1 day

3.96%

5 days

-2.88%

1 month

48.43%

3 months

-6.35%

6 months

-47.09%

Year to date

-70.09%

1 year

-85.7%

5 years

-99.97%

10 years

-99.99%

About: Intelligent Bio Solutions Inc is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its current active product is the Intelligent Fingerprinting Platform, consisting of a proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its flagship product, the Intelligent Fingerprinting Drug Screening System, is a two-part system of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Company operates in APAC, the UK, the Americas, and the rest of the world, with maximum revenue from the United Kingdom.

Employees: 60

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 10%

Neutral 90%

Negative 0%

Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth

Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units

Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth

Intelligent Bio Solutions Shares Surge Monday: What's Driving the Action?

Shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) are surging Monday afternoon after the medical technology company announced a significant regulatory milestone for its rapid testing unit.

Intelligent Bio Solutions Shares Surge Monday: What's Driving the Action?

Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification

Recertification aligns with the FDA's newly amended Quality Management System Regulation and supports the Company's regulatory strategy as it pursues FDA clearance Recertification aligns with the FDA's newly amended Quality Management System Regulation and supports the Company's regulatory strategy as it pursues FDA clearance

Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification

Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of its Usability Study for the Intelligent Fingerprinting Drug Screening System, supporting its FDA 510(k) submission for U.S. market clearance for detection of the opiate codeine. The study was conducted in partnership with CenExel Clinical Research, Inc., following FDA guidance and ICH GCP (International Council for Harmonisation Good Clinical Practice) standards.

Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission

Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the completion of its Interference Study for the Intelligent Fingerprinting Drug Screening System. The study supports the Company's FDA 510(k) submission for U.S. market clearance for detection of the opiate codeine.

Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System

Intelligent Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry

Company has addressed final review items from penetration testing and finalized cybersecurity and software documentation

Intelligent Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry

Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market

Precision testing confirms reproducibility across more than 1,600 tests, three production runs, and three independent testing sites Precision testing confirms reproducibility across more than 1,600 tests, three production runs, and three independent testing sites

Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings

Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV. Conference Details Date: June 16-18, 2026 Location: Bellagio Hotel & Casino, Las Vegas Presentation Date and Time: Wednesday, June 17, 2026, at 8:00 – 8:30 AM PDT Presentation Location: Track 7 – Donatello 3 Registration: Interested investors can register to attend here Webcast: Viewable here Booth: 413 The Company will be participating in one-on-one investor meetings throughout the event.

Intelligent Bio Solutions to Participate in Planet MicroCap Las Vegas Conference over June 16-18

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

Study designed to validate accuracy and real-world workplace performance of the Intelligent Fingerprinting Drug Screening System Company expects to complete enrollment and data collection by the end of July, 2026 NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the initiation of a multi-site Method Comparison Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for the opiate codeine. The Company has partnered with nationwide clinical research site network, CenExel Clinical Research, Inc., to perform the study, which will evaluate the accuracy of the Intelligent Fingerprinting Drug Screening System when operated by intended end-users across multiple clinical sites.

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

See News Rankings

Price charts implemented using Lightweight Charts™